



United Republic of Tanzania
Support for Vaccine: Rotavirus

This Decision Letter sets out the Programme Terms of a Programme

This Decision Letter forms part of the Partnership Framework Agreement and together with the Partnership Framework Agreement sets out the Programme Terms of the Programme. Any term used in this Decision Letter but not defined shall have the meaning given to such term in the Partnership Framework Agreement. The English language version of this Decision Letter shall prevail in the case of any conflict with terms expressed in any other language.

1. Country: United Republic of Tanzania

2. Vaccine grant number: TZA-RV-R

3. Date of Decision Letter¹: 18 January 2023

4. Date of the Partnership Framework Agreement (the "PFA"): 01 July 2013

5. Programme title: New Vaccine Support (NVS), Rotavirus, Routine

6. Vaccine type: Rotavirus

7. Requested product presentation and formulation of vaccine:

Rvac, 5 doses/vial, frozen

Rvac, 5 doses/vial, liquid

8. Programme duration:² 2013-2027

9. Programme Budget (indicative): (subject to the terms of the PFA)

This is the total amount approved by Gavi for the entire duration of the programme. Annual amounts are defined as per section 4.1 of the PFA. The annual amounts are indicative and not limited for use for the specified year. Any requested adjustments to the Annual Amounts will be subject to Gavi approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the Programme. Further, amounts are indicative and are subject to the availability of funds and relevant approvals by the Gavi Board.

¹ This Decision Letter will apply for the programme duration. Gavi will only update this Decision Letter in the event of the following: i) release of future year approvals; ii) adjustments to initial quantities; iii) product price changes or product switches; and/or iv) co-financing amounts.

² This is the entire duration of the programme.

	2013-2022	2023	2024	2025	2026	Total
Programme Budget (US\$)	80,859,096	6,389,598	7,564,559	-	-	94,813,253

10. Vaccine introduction grant:

Approval		
Year	Grant number	Amount (US\$)
2013	TZA-RV-R-VIG-WHO	1,580,000

11. Product switch grant:

Approval		
Year	Grant number	Amount (US\$)
2022	TZA-RV-R-PSG	599,233
2023	TZA-RV-R-PSG	516,861
Total Amount (US\$)	TZA-RV-R-PSG	1,116,094

12. Indicative annual amounts: (subject to the terms of the PFA)

Gavi Support	2013-2022	2023		2024		2025		2026		2027	
		Units	Total cost (US\$)	Units	Total cost (US\$)	Units	Total cost (US\$)	Units	Total cost (US\$)	Units	Total cost (US\$)
Rvac, 5 doses/vial, frozen	-	7,103,500	6,037,975	-	-	-	-	-	-	-	-
Rvac, 5 doses/vial, liquid	-	-	-	6,203,000	7,133,450	-	-	-	-	-	-
Freight costs - doses	-	1	351,623	1	431,109	-	-	-	-	-	-
Total Amounts (US\$)	80,859,096		6,389,598		7,564,559						

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

14. Self-procurement:

Not applicable

15. Co-financing obligations (indicative)¹

¹ Gavi may adjust the outlined co-financing obligations based on the corresponding actual dose shipments to the country. Any over/under co-financed doses/amounts will be settled in subsequent payments.

According to the co-financing policy, the Country falls within the group: Preparatory Transition										
Co-Finance Obligation	2023		2024		2025		2026		2027	
	Units	Total cost (US\$)	Units	Total cost (US\$)	Units	Total cost (US\$)	Units	Total cost (US\$)	Units	Total cost (US\$)
Rvac, 5 doses/vial, frozen	788,500	670,225	-	-	-	-	-	-	-	-
Rvac, 5 doses/vial, liquid	-	-	803,000	923,450	-	-	-	-	-	-
Freight costs - doses	1	109,956	1	153,734						
Total Amounts (US\$)		780,181		1,077,184						

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

Reports and other information:	Due dates
To enable the annual release of purchase orders, Country shall report closing stock levels by 31 March of each calendar year ¹ ;	31 March
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

For Gavi: signed by



Colette Selman
Director, Core Countries

¹ Reporting requirements are subject to change. Countries may be required to submit quarterly or monthly stock reports. Country will be notified of updated reporting requirements separately.